DDInter1834 DDInter1094
Topiramate is a anti-epileptic drug used to manage seizures and prevent migraines. It was initially approved by the FDA in 1996. In 2004, topiramate was approved for the prevention of migraine in adults.[A188309,L10544,L43478] Since 2012, the extended-release formulation has been approved in combination with [phentermine] for chronic weight management therapy in adults. Characteristics that distinguish topiramate from other antiepileptic drugs are a monosaccharide chemical structure containing a sulfamate, and 40% of its mass accounted for by oxygen. Interestingly, topiramate was discovered by chance when attempts were made to formulate a novel antidiabetic drug.
Lorlatinib is a third-generation ALK tyrosine kinase inhibitor (TKI) for patients with ALK-positive metastatic non-small cell lung cancer which was first approved by the US FDA in November of 2018. It was subsequently approved by the EMA in 2019 for the treatment of select patients with previously treated advanced ALK-positive non-small cell lung cancer, followed by an expanded approval in 2022 to include lorlatinib as a first-line treatment option in advanced ALK-positive NSCLC.
Topiramate {u} (Compound) binds {v} (Gene) SCN5A
SCN5A {u} (Gene) is bound by {v} (Compound) Lidocaine
Lidocaine {u} may cause a minor interaction that can limit clinical effects when taken with {v} Lorlatinib
Topiramate {u} (Compound) binds {v} (Gene) SCN5A
SCN5A {u} (Gene) is bound by {v} (Compound) Disopyramide
Disopyramide {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Lorlatinib
Topiramate {u} (Compound) causes {v} (Side Effect) Nausea
Nausea {u} (Side Effect) is caused by {v} (Compound) Lidocaine
Lidocaine {u} may cause a minor interaction that can limit clinical effects when taken with {v} Lorlatinib
Topiramate {u} (Compound) binds {v} (Gene) SCN5A
SCN5A {u} (Gene) is bound by {v} (Compound) Phenytoin
Phenytoin {u} may lead to a major life threatening interaction when taken with {v} Lorlatinib
Topiramate {u} (Compound) causes {v} (Side Effect) Urticaria
Urticaria {u} (Side Effect) is caused by {v} (Compound) Triamcinolone
Triamcinolone {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Lorlatinib
Topiramate {u} (Compound) causes {v} (Side Effect) Hypoaesthesia oral
Hypoaesthesia oral {u} (Side Effect) is caused by {v} (Compound) Fentanyl
Fentanyl {u} may lead to a major life threatening interaction when taken with {v} Lorlatinib
Topiramate {u} (Compound) treats {v} (Disease) obesity
obesity {u} (Disease) is treated by {v} (Compound) Sibutramine
Sibutramine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Lorlatinib
Topiramate {u} (Compound) treats {v} (Disease) epilepsy syndrome
epilepsy syndrome {u} (Disease) is treated by {v} (Compound) Phenytoin
Phenytoin {u} may lead to a major life threatening interaction when taken with {v} Lorlatinib
Topiramate {u} (Compound) treats {v} (Disease) migraine
migraine {u} (Disease) is palliated by {v} (Compound) Methylergometrine
Methylergometrine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Lorlatinib
Topiramate {u} (Compound) upregulates {v} (Gene) UBQLN2
UBQLN2 {u} (Gene) is upregulated by {v} (Compound) Ifosfamide
Ifosfamide {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Lorlatinib
Topiramate (Compound) binds SCN5A (Gene) and SCN5A (Gene) is bound by Lidocaine (Compound) and Lidocaine may cause a minor interaction that can limit clinical effects when taken with Lorlatinib
Topiramate (Compound) binds SCN5A (Gene) and SCN5A (Gene) is bound by Disopyramide (Compound) and Disopyramide may cause a moderate interaction that could exacerbate diseases when taken with Lorlatinib
Topiramate (Compound) causes Nausea (Side Effect) and Nausea (Side Effect) is caused by Lidocaine (Compound) and Lidocaine may cause a minor interaction that can limit clinical effects when taken with Lorlatinib
Topiramate (Compound) binds SCN5A (Gene) and SCN5A (Gene) is bound by Phenytoin (Compound) and Phenytoin may lead to a major life threatening interaction when taken with Lorlatinib
Topiramate (Compound) causes Urticaria (Side Effect) and Urticaria (Side Effect) is caused by Triamcinolone (Compound) and Triamcinolone may cause a moderate interaction that could exacerbate diseases when taken with Lorlatinib
Topiramate (Compound) causes Hypoaesthesia oral (Side Effect) and Hypoaesthesia oral (Side Effect) is caused by Fentanyl (Compound) and Fentanyl may lead to a major life threatening interaction when taken with Lorlatinib
Topiramate (Compound) treats obesity (Disease) and obesity (Disease) is treated by Sibutramine (Compound) and Sibutramine may cause a moderate interaction that could exacerbate diseases when taken with Lorlatinib
Topiramate (Compound) treats epilepsy syndrome (Disease) and epilepsy syndrome (Disease) is treated by Phenytoin (Compound) and Phenytoin may lead to a major life threatening interaction when taken with Lorlatinib
Topiramate (Compound) treats migraine (Disease) and migraine (Disease) is palliated by Methylergometrine (Compound) and Methylergometrine may cause a moderate interaction that could exacerbate diseases when taken with Lorlatinib
Topiramate (Compound) upregulates UBQLN2 (Gene) and UBQLN2 (Gene) is upregulated by Ifosfamide (Compound) and Ifosfamide may cause a moderate interaction that could exacerbate diseases when taken with Lorlatinib